- Gai Z, Dong Y, Xu F, Zhang J, Yang Y, Wang Y. Changes in the gut microbiota composition of healthy young volunteers after administration of Lacticaseibacillus rhamnosus LRa05: A placebo-controlled study. Front Nutr. 2023 Mar 14;10:1105694. doi: 10.3389/fnut.2023.1105694. PMID: 36998912; PMCID: PMC10043436.
- Majeed M, Nagabhushanam K, Natarajan S, Sivakumar A, Ali F, Pande A, Majeed S, Karri SK. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study. Nutr J. 2016
- Majeed M, Nagabhushanam K, Paulose S, Arumugam S, Mundkur L. The effects of Bacillus coagulans MTCC 5856 on functional gas and bloating in adults: A randomized, double-blind, placebo-controlled study. Medicine (Baltimore). 2023
Trusted for: N/A|
Price: £17.09 per month*
Date reviewed: 10/2023
- Delayed release capsule
- Promotes the growth of friendly bacteria
(*) = price based on subscription
What's in it?
Bacterial Blend (Lactobacillus acidophilus-LA85 (33 Million CFU), Streptococcus thermophilus-ST81 (1.3 Billion CFU), Bifidobacterium bifidum-BBi32 (1.3 Billion CFU), Lactobacillus rhamnosus (Lacticaseibacillus rhamnosus)–LRa05 (1.3 Billion CFU), Lactobacillus plantarum (Lactiplantibacillus plantarum)–Lp90 (1.3 Billion CFU), Bifidobacterium breve-BBr60 (1.3 Billion CFU), Bifidobacterium longum-BL21 (1.3 Billion CFU), Lactobacillus casei (Lacticaseibacillus casei)-LC89 (1.3 Billion CFU), Lactococcus lactis-LLa61 (1.3 Billion CFU), Lactobacillus reuteri (Limosilactobacillus reuteri)-LR08 (1.3 Billion CFU), Lactobacillus brevis (Levilactobacillus brevis)-LB01 (1.3 Billion CFU), Lactobacillus bulgaricus (Lactobacillus delbrueckii subsp. bulgaricus)–LB42 (1.3 Billion CFU), Lactobacillus salivarius (Ligilactobacillus salivarius)-LS97 (1.3 Billion CFU), Bifidobacterium lactis-BLa80 (1.3 Billion CFU), Lactobacillus helveticus-LH76 (1.3 Billion CFU), Bifidobacterium infantis-BI45 (1.7 Billion CFU), Bifidobacterium adolescentis-BAc30 (1.3 Billion CFU), Lactobacillus gasseri-LG08 (1.7 Billion CFU), Lactobacillus crispatus-LCr86 (1.3 Billion CFU), Lactobacillus paracasei (Lacticaseibacillus paracasei)-LC86 (3.3 Billion CFU)), Bacillus coagulans (LactoSpore) 1 Billion CFU, Bulking agents (Calcium phosphates, Microcrystalline cellulose), Vegetable Delayed Release capsule shell (Hydroxypropyl methyl cellulose, Gelling agent: Gellan gum), Inulin (100 mg), Rice hulls, Rice Extract Blend (Rice Extract, Rice Hulls, Sunflower Oil).
What does the research say?
This product and its specific combination of bacteria has not been studied clinically. To our knowledge, only two strains in this product have been studied in humans.
Bacillus coagulans MTCC5856 (LactoSpore) is a probiotic which has been shown to potentially help with symptoms of bloating and gas in randomized, controlled trials at a dose of 2 billion CFU per day. However, the dose in this product is lower (1 billion CFU per day).
A randomized, controlled trial in 100 participants showed that Lacticaseibacillus rhamnosus–LRa05 may be able to colonise the gut in healthy adults, but no other benefits were observed, and the strain was administered at a dose of 10 billion CFU, which is approximately 10 x higher than the in the product (1.3 Billion CFU).
To our knowledge, none of the other strains in this product have been studied in human clinical trials.
The dose of inulin in this product (100mg) is likely too low to have any prebiotic effects when compared to clinical trials.
This product by Nutravita contains a majority of strains that have not been tested in humans. Those strains that have been studied may be at too low of a dose to have any clinical benefit. Therefore, this product needs to first be investigated clinically before claims can be supported.
Reviews are for informational purposes only and do not constitute medical advice
Got a product you want us to test? Or a topic you want to know more about? We want to hear it!